e-learning
resources
Vienna 2009
Wednesday, 16.09.2009
Mechanisms of infection: what's new?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A model of poly IC-driven exacerbations of smoke-induced pulmonary inflammation – does it meet researchers needs?
R. U. Schaefer, B. Jung (Biberach/Riss, Germany)
Source:
Annual Congress 2009 - Mechanisms of infection: what's new?
Session:
Mechanisms of infection: what's new?
Session type:
E-Communication Session
Number:
4773
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. U. Schaefer, B. Jung (Biberach/Riss, Germany). A model of poly IC-driven exacerbations of smoke-induced pulmonary inflammation – does it meet researchers needs?. Eur Respir J 2009; 34: Suppl. 53, 4773
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Targeting the IL-1β – IL-17A inflammatory axis for the treatment of viral-induced exacerbations of COPD
Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Year: 2012
Role of IL-1α and IL-1β in cigarette smoke-induced pulmonary inflammation and COPD
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011
Role of IL-1? and the Nlrp3/caspase-1/IL-1? axis in cigarette smoke-induced pulmonary inflammation and COPD
Source: Eur Respir J 2011; 38: 1019-1028
Year: 2011
Chronic non-asthmatic cough – Are we nearer to define the airway pathology?
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
IL-23 is essential to the development of elastase-induced pulmonary inflammation and emphysema
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Beyond corticosteroids: future prospects in the management of inflammation in COPD
Source: Eur Respir Rev 2011; 20: 175-182
Year: 2011
Halotherapy – A possible method to enhance airway treatment on patients with obstructive pathology
Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use
Year: 2012
Cigarette smoke induced pulmonary emphysema is attenuated in CCR6 deficient mice
Source: Annual Congress 2006 - Cell biology of asthma and COPD
Year: 2006
Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Evasion of COPD in smokers: at what price?
Source: Eur Respir J 2012; 39: 1298-1303
Year: 2012
Modulation of airway inflammation to prevent exacerbations of COPD
Source: Eur Respir Rev 2005; 14: 78-82
Year: 2005
Cigarette smoke-induced pulmonary inflammation, but not airway wall remodeling, is attenuated in CCR5 deficient mice
Source: Annual Congress 2007 - The best of airway epithelial cells
Year: 2007
Expression of MIC-A in bronchial epithelium associates with cigarette smoking: a sign of induced autoimmune mechanisms?
Source: Annual Congress 2005 - Lung structure: current concepts
Year: 2005
Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives
Source: Eur Respir Rev 2015; 24: 594-601
Year: 2015
Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation
Source: International Congress 2014 – Animal models: asthma, COPD and beyond
Year: 2014
Differences in the polarization of the inflammatory response of patients with chronic obstructive pulmonary disease (COPD) secondary to smoking and to biomass smoke exposure
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease
Year: 2021
LSC 2010 Abstract: Synthetic dsRNA exacerbates pulmonary inflammation in acute and sub-chronic
in vivo
models of COPD
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Why is it important to consider (sub)phenotypes of asthma and COPD?
Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not?
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept